Pulmocide

OverviewSuggest Edit

Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. 
Unlike currently available treatments for fungal and viral infections in the lung, the company's innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects.
Pulmocide is generating a pipeline of novel, potent first-in-class anti-infective agents for delivery by inhaled administration for the treatment of life-threatening lower respiratory tract viral and fungal infections.

TypePrivate
Founded2013
HQLondon, GB
Websitepulmocide.com

Latest Updates

Employees (est.) (Jan 2021)15
Cybersecurity ratingAMore

Key People/Management at Pulmocide

Dan Burgess

Dan Burgess

Chairman and Chief Executive Officer
Alison Murray

Alison Murray

Chief Medical Officer
Kaz Ito

Kaz Ito

Director of Biology
Matthew Foy

Matthew Foy

Non Executive Director
David Mantus

David Mantus

President, US Operations
Pete Strong

Pete Strong

Chief Scientific Officer and Co-Founder
Show more

Pulmocide Office Locations

Pulmocide has an office in London
London, GB (HQ)
265 Strand
London, GB
44 Southampton Buildings, Holborn
Show all (2)

Pulmocide Financials and Metrics

Summary Metrics

Founding Date

2013

Pulmocide total Funding

$57.5 m

Pulmocide latest funding size

$30 m

Time since last funding

4 years ago

Pulmocide investors

Pulmocide's latest funding round in March 2017 was reported to be $30 m. In total, Pulmocide has raised $57.5 m
Show all financial metrics

Pulmocide Revenue

Cash (31-Mar-2019)

5.2m
GBPFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

7.1m3.2m13.3m13.0m5.2m

Current Assets

7.4m3.8m13.7m16.1m7.6m
FY, 2015

Financial Leverage

-1.1 x
Show all financial metrics

Pulmocide Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Pulmocide Online and Social Media Presence

Embed Graph

Pulmocide News and Updates

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide

Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide

Pulmocide Blogs

Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections

London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, today announces the publication of two papers in key scientific journals featuring Pulmocide’s lead drug candidate, PC945. PC945 is the f…

Pulmocide Presents at US FDA Workshop on Inhaled Antifungal Drug Development

London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening lung infections, is pleased to announce that the company was invited to present at the The Food and Drug Administration (FDA) virtual public wo…

Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence

London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published in the Journal of Antimicrobial Chemotherapy highlight the potential of its novel ant…

Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus

Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of invasive fungal lung infections, announces the publication of data demonstrating the synergistic antifungal effect of combining topical administration of PC945, its novel inhaled triazole, with system…

Pulmocide at the upcoming Respiratory Innovation Summit in Dallas on May 17!

We are honoured to have been selected to tell our story at the upcoming Respiratory Innovation Summit on May 17! RIS Agenda Pulmocide’s CSO, Dr. Pete Strong will be presenting  at the RIS. The post Pulmocide at the upcoming Respiratory Innovation Summit in Dallas on May 17! appeared first on Pulmoci…

Royal Brompton and Harefield NHS team presented the first case report of the inhaled anti-fungal PC945, at the Fungal Update meeting held in London on 15th-16th March, 2019.

Fungal Update Meeting This is the first report describing the use of PC945 treatment for refractory Aspergillus bronchial anastomotic infection and tracheobronchitis in a lung transplant patient. Treatment was highly effective in the clearance of visible signs of infection and was well tolerated   P…
Show more

Pulmocide Frequently Asked Questions

  • When was Pulmocide founded?

    Pulmocide was founded in 2013.

  • Who are Pulmocide key executives?

    Pulmocide's key executives are Dan Burgess, Alison Murray and Kaz Ito.

  • How many employees does Pulmocide have?

    Pulmocide has 15 employees.

  • Who are Pulmocide competitors?

    Competitors of Pulmocide include Alembic Pharmaceuticals, EMS Pharma and Biocon.

  • Where is Pulmocide headquarters?

    Pulmocide headquarters is located at 265 Strand, London.

  • Where are Pulmocide offices?

    Pulmocide has an office in London.

  • How many offices does Pulmocide have?

    Pulmocide has 2 offices.